DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for esophageal squamous cell carcinoma — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEsophageal squamous cell carcinoma maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for esophageal squamous cell carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CREB binding lysine acetyltransferase (CREBBP) — CREBBP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1vudrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9H0K · 1.75 Å · ligand propionyl Coenzyme A (1VU). Experimental structure, not a prediction.
What the evidence adds up to
Esophageal squamous cell carcinoma is the most common histotype of oesophageal cancer worldwide, yet no significant targeted therapy has been introduced into clinical practice despite comprehensive molecular characterisation. The five-year survival remains below 20% and has not significantly improved in recent decades. Over 80% of oesophageal cancers are squamous cell carcinomas, and the disease is the leading cause of cancer-related death in epidemic regions such as northern China. The geographical incidence of squamous cell carcinoma has been the most varied of any cancer for many decades, suggesting critically important but largely unclear environmental and molecular factors.
Genomic lesions drive the metastasis of oesophageal squamous cell carcinoma, and the need for better characterisation of the molecular basis of pathogenesis is stated as necessary. A 2024 review notes that recent advances in therapeutic agents and numerous randomised controlled trials have changed the landscape of systemic therapy, particularly through the inclusion of immunotherapy, which permits improved patient management in multiple settings. That review gives an overview of standard-of-care treatment and sheds light on new therapeutic options, recently approved treatments, and ongoing trials.
No concrete numbers for response rates or survival improvements from any specific drug are provided in these abstracts. The 2024 review does not name which immunotherapies or targeted agents have been approved or trialled, nor does it report any efficacy data. The 2003 and 2017 abstracts emphasise that the molecular drivers remain largely unclear and that no targeted therapy has reached the clinic.
What is still missing is a clear, actionable set of molecular targets that can be drugged in a substantial fraction of patients, along with the trial designs and patient stratification strategies needed to test them. The lack of concrete efficacy data from these summaries underscores that the field remains in a discovery and early validation phase, not a treatment recommendation phase.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancers · 2020 · 44 citations · open access
The Pathologic and Molecular Landscape of Esophageal Squamous Cell Carcinogenesis
AbstractEsophageal squamous cell carcinoma represents the most common histotype of epithelial neoplasm occurring within esophageal mucosa worldwide. Despite the comprehensive molecular characterization of this entity, to date no significant targeted therapy has been introduced into clinical practice. In this review, we describe the molecular landscape of esophageal squamous cell carcinoma based on the most recent literature. Moreover, we focus on other rare variants and on the relationship with head and neck squamous cell carcinomas.
Journal of Thoracic Disease · 2017 · 5 citations · open access
Genomic lesions drive the metastasis of esophageal squamous cell carcinoma
AbstractEsophageal cancer ranks sixth in terms of cancer-associated mortality (1). The majority (over 80%) of esophageal cancers are squamous cell carcinomas (ESCC) (2), which is the leading cause of cancer-related death in its epidemic regions, such as northern China. Even with the advent of modern therapeutic approaches, the 5 years survival of ESCC (<20%) has not significantly improved in the past few decades. These facts necessitate the need for better characterization of the molecular basis of ESCC pathogenesis.
memo - Magazine of European Medical Oncology · 2024 · 1 citations · open access
State-of-the-art therapy and innovative treatment strategies in esophageal squamous cell cancer
AbstractSummary Recent advances in the development of new therapeutic agents and the execution of numerous randomized controlled trials have changed the landscape of systemic therapy approaches in patients with esophageal squamous cell cancer (ESCC). Particularly the inclusion of immunotherapy permits clinicians to improve patient management in multiple settings. This review gives an overview of standard-of-care treatment and sheds light on new therapeutic options, recently approved treatments, and ongoing trials.
Epidemiology and Molecular Epidemiology of Esophageal Cancer
AbstractAbstract The two main histopathologic types of esophageal cancer are squamous cell carcinoma (SCC) and adenocarcinoma. Squamous cell carcinoma is the more prevalent type worldwide, but adenocarcinoma is more prevalent in many Western countries. Both SCC and adenocarcinoma of the esophagus have remarkable epidemiologic features. Squamous cell carcinoma has had the most varied geographical incidence of any cancer for many decades, which suggests the existence of critically important, but largely unclear, environmental and molecular factors.
Journal of Medical Cases · 2014 · 0 citations · open access
A Case of Esophageal Squamous Cell Cancer in an Endoscopically Normal Esophagus
AbstractEsophageal squamous cell carcinoma (ESCC) has traditionally been detected in the later stages of disease which requires aggressive treatment. Newer endoscopic methods have allowed gastroenterologists to detect ESCC lesions and start treatment earlier with the hope to avoid more difficult treatments such as esophagectomy, chemotherapy and radiation. This report follows a patient from detection of ESCC through successful treatment of the ESCC lesions . J Med Cases. 2014;5(4):224-226 doi: http://dx.doi.org/ 10.14740 /jmc1724w
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
